Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Coley Pharmaceutical Group, Pfizer deal

PFE will acquire COLY for $8 per share in cash. The deal values COLY at $230 million, or $164 million net of COLY's cash. The price is a 167% premium to

Read the full 319 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE